Podcast

Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Author(s):

Urology Times staff

In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

Related Videos
4 experts in this video
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Laura Davis, MD, on link between microplastics and bladder cancer
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Study data point to gender disparities in oncology research citations
Study data point to gender disparities in oncology research citations
Related Content
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
May 21st 2025

FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

Hannah Clarke
The committee voted 4-5 in opposition of a favorable benefit-risk profile.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD
Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
May 9th 2025

Durvalumab plus BCG significantly improves DFS in NMIBC

Benjamin P. Saylor Hannah Clarke
The data are to be presented at an upcoming medical conference.
Physical function and frailty measures offer distinct insights in patients with bladder cancer
May 7th 2025

Physical function and frailty measures offer distinct insights in patients with bladder cancer

Hannah Clarke
Data showed that physical function and self-reported frailty assessments were poorly correlated.
© 2025 MJH Life Sciences

All rights reserved.